Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

Vaccine. 2005 May 9;23(25):3256-63. doi: 10.1016/j.vaccine.2005.01.089.


Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990-2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged > or =60 years than among those 19-29 years of age (reporting rate ratio = 5.9, 95% CI 1.6-22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Child
  • Child, Preschool
  • Female
  • Hepatitis A Vaccines / adverse effects
  • Humans
  • Infant
  • Logistic Models
  • Male
  • Middle Aged
  • Military Personnel
  • Nervous System Diseases / etiology
  • Population Surveillance
  • Risk Factors
  • Travel
  • Typhoid-Paratyphoid Vaccines / adverse effects
  • United States / epidemiology
  • Yellow Fever Vaccine / adverse effects*


  • Hepatitis A Vaccines
  • Typhoid-Paratyphoid Vaccines
  • Yellow Fever Vaccine